SJATRT: Phase II Study of Alisertib As A Single Agent in Recurrent or Progressive Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT


Brain Tumor : Recurrent, progressive, or newly diagnosed Atypical Teratoid Rhabdoid Brain Tumors (ATRT)
Solid Tumor : Progressive extra-CNS Malignant Rhabdoid Solid Tumors (MRT)


This study will treat participants with progressive ATRT or MRT (Stratum A) and participants with newly diagnosed ATRT (Strata B and C).

The main goal of this study is to find out what effects alisertib has (good and bad) when given as a single agent to participants with progressive disease or when added to chemotherapy for participants with newly diagnosed ATRT. Some participants will also get radiation to brain and/or spine depending on their age.

Alisertib is an investigational drug that is shown in laboratory studies to block a protein called aurora A kinase. Aurora A kinase is a protein that is found in the cells of the body when they divide and multiply. Aurora A kinase may also partly control the ability of certain cancers to grow. Alisertib has been used in only a small number of adults and children, and there is a lot that is not known about this drug.


Eligibility criteria, among others, include:


Alberto Broniscer, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN  38105 USA
Phone: (901) 595-2544 or (901) 595-4599
FAX: (901) 595-6211


Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: (901) 595-2544
FAX: (901) 595-6211

For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.